Related Experiment Video
Updated: Jul 15, 2026
05:52
Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
Is sentinel lymph node mapping in colorectal cancer a future prognostic factor? A meta-analysis
Gaëtan Des Guetz1, Bernard Uzzan, Patrick Nicolas
1Department of Oncology, Hôpital Avicenne AP-HP, 125 Route de Stalingrad, Bobigny, France. Gaetan.des-guetz@avc.aphp.fr
World Journal of Surgery
|April 27, 2007
Summary
Sentinel lymph node mapping (SLNM) shows potential for diagnosing colorectal cancer (CRC) but requires standardization. Further research is needed to understand false negatives before routine use in CRC management.
Area of Science:
- Oncology
- Surgical Pathology
Background:
- Sentinel lymph node mapping (SLNM) is a technique used to identify the primary lymph node(s) draining a tumor site.
- Its diagnostic value in colorectal cancer (CRC) remains debated, necessitating further investigation into prognostic factors for improved CRC treatment.
Purpose of the Study:
- To evaluate the diagnostic accuracy of SLNM compared to conventional histopathologic examination in patients with colorectal cancer.
- To determine the overall sensitivity, specificity, and failure rate of SLNM in CRC detection.
Main Methods:
- A systematic review and meta-analysis of PubMed-indexed studies and retrieved reviews on SLNM for CRC.
- Statistical analysis using the diagnostic accuracy odds ratio (DAOR) method and a random-effects model on 33 selected studies involving 1794 patients.
Main Results:
- The pooled analysis included 33 studies with 1794 patients, revealing a mean SLNM failure rate of 10%.
- Overall sensitivity was 70% and specificity was 81%.
- The pooled diagnostic accuracy odds ratio (DAOR) was 10.7, indicating a significantly higher risk of node positivity in SLN-invaded patients.
Conclusions:
- Sentinel lymph node mapping is applicable to colorectal cancer, with a pooled DAOR of 10.7.
- Significant heterogeneity exists, partly due to variations in SLNM performance; standardization is crucial.
- Further research is required to address false-negative rates and the prognostic significance of micrometastases for routine clinical application.
